Sumitomo Pharma Co., Ltd., trading OTC under the ticker DNPUF, is a global pharmaceutical company headquartered in Osaka, Japan. It engages in the research, development, manufacturing and marketing of prescription medicines. As part of the broader Sumitomo Group, the company applies integrated drug discovery platforms and collaborative partnerships to bring innovative therapies to market.
The company’s portfolio encompasses central nervous system disorders, oncology, immunology and regenerative medicine. Sumitomo Pharma develops small molecules and biologics for conditions such as depression, schizophrenia, epilepsy and various solid tumors. In addition to its in-house pipeline, the company pursues strategic licensing agreements and joint research initiatives to enhance its product offerings, while exploring emerging modalities including gene therapy and digital health solutions.
Sumitomo Pharma maintains research and production facilities in Japan and operates subsidiaries across North America, Europe and the Asia-Pacific region, notably Sunovion Pharmaceuticals, Inc. in the United States. Its global sales and distribution network spans over 30 countries, supported by regional R&D hubs in major life-science centers to accelerate clinical development and regulatory approvals.
Formed in October 2005 through the merger of Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceuticals Co., Ltd., the company’s lineage dates to the late 19th century. Led by an Osaka-based executive team, Sumitomo Pharma continues to prioritize scientific innovation, patient-centered therapies and sustainable growth in the international biopharmaceutical landscape.
AI Generated. May Contain Errors.
